Human CellExp CD319 / SLAMF7 / CRACC, human recombinant protein
SLAMF7, CD319, CS1, CRACC, 19A, FOAP-12
|Calculated MW||This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 23.2 kDa. The predicted N-terminus is Ser 23. DTT-reduced Protein migrates as 33-48 kDa due to glycosylation.|
|Other Names||SLAMF7, CD319, CS1, CRACC, 19A, FOAP-12|
|Results||Measured by its ability to bind biotinylated human SLAMF7 in a functional ELISA.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.
Boles K.S.,et al.Immunogenetics 52:302-307(2001).
Bouchon A.,et al.J. Immunol. 167:5517-5521(2001).
Murphy J.J.,et al.Biochem. J. 361:431-436(2002).
Fujii Y.,et al.Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
Clark H.F.,et al.Genome Res. 13:2265-2270(2003).
If you have any additional inquiries please email technical services at email@example.com.